Slide 1: SELECT-AML-1: Initial Randomized Data Evaluating Tamibarotene in Newly Diagnosed AML
SELECT-AML-1: Initial Randomized Data Evaluating Tamibarotene in Newly Diagnosed AML Patients Ineligible for Standard Induction Therapy December 6, 2023 Exhibit 99.1
Slide 2: Forward-looking statements
Forward-looking statements This presentation contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended) concerning Syros and other matters, such as Syros’ clinical dev
Slide 3: Developing new standards of care for frontline treatment of hematologic malignancies
Developing new standards of care for the frontline treatment of patients with hematologic malignancies Robert MDS Patient Dan AML Patient with his wife Renée AML patient with her daughter of patients with HR-MDS are positive for RARA overexpression1 ~50% ~30% of patients with AML are positive for RA
Slide 4: Significant unmet need in newly diagnosed unfit AML and higher-risk MDS
Significant unmet need in newly diagnosed unfit AML and higher-risk MDS 1DiNardo CD, et al., Cancer. 22022 Garcia, J et al., Leukemia Research, 2021; 3 DiNardo CD, et al., New England Journal of Medicine, 2020; 4Maiti A., et al., Haematologica, 2021. Higher-risk MDS (HR-MDS) is closely related to AM
Slide 5: Tamibarotene: Novel, targeted mechanism of action provides competitive differentiation
Biologically targeted1 High complete response rates2,3 Rapid time to response2,3 Favorable tolerability2,3,4 Readily combinable2,3,4 No additive myelosuppression2,3 Tamibarotene: Novel, targeted mechanism of action provides competitive differentiation Tamibarotene is a selective and potent RARa agon
Slide 6: 100% CR/CRi rate observed in initial data from randomized SELECT-AML-1 Phase 2 trial
100% CR/CRi rate observed in initial data from randomized SELECT-AML-1 Phase 2 trial in newly diagnosed unfit AML patients with RARA overexpression CR/CRi Rate 70% CR/CRi Rate 100% CONTROL ARM: Ven/Aza TREATMENT ARM: Tami/Ven/Aza Tamibarotene in combination with venetoclax and azacitidine was well t
Slide 7: SELECT-AML-1 randomized trial design
SELECT-AML-1 randomized trial design Part 3: Trial includes a cohort in which the triplet will be evaluated as a salvage strategy for patients in venetoclax+azacitidine control arm who experience progressive disease, relapse, or treatment failure 28 sites across the US and France are open for recrui
Slide 8: Patients randomized into SELECT-AML-1 trial
23 patients randomized into SELECT-AML-1 trial . 3 Tami/Ven/Aza patients non-evaluable 2 recently enrolled and have not reached the initial response assessment as of the November 13, 2023 data cut-off 1 patient discontinued during cycle 1 (prior to starting tamibarotene) without a response assessmen
Slide 9: Enrolled patients representative of elderly unfit AML patient population
Enrolled patients representative of elderly unfit AML patient population and demonstrated balanced randomization across the two arms Characteristic Tami/Ven/Aza N=12 Ven/Aza N=11 Median age, years (range) 77 (66, 85) 76 (69, 84) Age group, years, n (%) ≤75 4 (33) 5 (45) >75 8 (67) 6 (55) Sex, n (%)
Slide 10: Triplet regimen associated with 100% CR/CRi rate and rapid onset of response
Triplet regimen associated with 100% CR/CRi rate and rapid onset of response Tami/Ven/Aza N=9* n (%) Ven/Aza N=10* n (%) Primary Endpoint CR/CRi Rate 9 (100%) 7 (70%) CR 7 (78%) 3 (30%) CRi 2 (22%) 4 (40%) Secondary Endpoints ORR^ 9 (100%) 8 (80%) CRh 0 1 (10%) MLFS 0 0 PR 0 0 Non-Responders Treatme
Slide 11: Hematologic safety profile: No additive myelosuppression
Hematologic safety profile: No additive myelosuppression when combining tamibarotene with venetoclax/azacitidine Febrile neutropenia Neutropenia Thrombocytopenia Leukopenia Anemia Hematologic AEs - All Causality Tami/Ven/Aza Safety Population, N=11; Ven/Aza Safety Population, N=12* * Includes 1 pati
Slide 12: Non-Hematologic safety profile: No additive toxicities or new safety signals
Non-Hematologic safety profile: No additive toxicities or new safety signals identified when combining tamibarotene with venetoclax/azacitidine The majority of non-hematologic AEs are low grade and reversible Rates of SAEs are comparable between arms Most frequent SAEs (occurring in >1 patient in t
Slide 13: Initial randomized clinical activity and safety data support potential for tamibarotene
Compelling initial randomized clinical activity and safety data support the potential for tamibarotene in frontline treatment of hematologic malignancies with RARA overexpression Tamibarotene/venetoclax/azacitidine demonstrated a high CR/CRi rate and a very rapid onset of response in newly diagnosed
Slide 14: Large market opportunities in frontline settings
Large market opportunities in frontline settings ~25,000 Newly Diagnosed Unfit AML patients in US and EU annually2 Building infrastructure to target synergistic patient populations underserved by existing options ~21,000 Newly Diagnosed HR-MDS patients in the US and EU annually1 ~$3.3B3 MYELODYSPLAS
Slide 15: Multiple near-term value-driving milestones and pre-launch activities underway
Multiple near-term value-driving milestones and pre-launch activities underway Last patient enrolled for the pivotal CR data from SELECT-MDS-1 Phase 3 trial Pivotal data from SELECT-MDS-1 Phase 3 trial Initial data from randomized SELECT-AML-1 trial Additional data from randomized SELECT-AML-1 trial
Slide 16: SYR2:S
SYR2:S